77 related articles for article (PubMed ID: 23471430)
1. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen.
Mayerhoefer ME; Ba-Ssalamah A; Weber M; Mitterhauser M; Eidherr H; Wadsak W; Raderer M; Trattnig S; Herneth A; Karanikas G
Eur Radiol; 2013 Jul; 23(7):1978-85. PubMed ID: 23471430
[TBL] [Abstract][Full Text] [Related]
2. Surgical evidence-based comparison of [
Li X; Lv X; Quan Z; Han T; Tang Y; Liu Y; Wang M; Li G; Ye J; Wang J; Lan X; Zhang X; Li M; Liu S; Kang F; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1773-1785. PubMed ID: 38197954
[TBL] [Abstract][Full Text] [Related]
3. The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1.
Gao J; Liu C; Zhou J; Pan Y; Zhang Y
J Med Imaging Radiat Oncol; 2024 Apr; 68(3):250-256. PubMed ID: 38563291
[TBL] [Abstract][Full Text] [Related]
4. Comparison of
Drucker Iarovich M; Hinzpeter R; Moloney BM; Hueniken K; Veit-Haibach P; Ortega C; Metser U
Curr Oncol; 2024 Jan; 31(1):521-534. PubMed ID: 38248121
[TBL] [Abstract][Full Text] [Related]
5. Head-to-Head Comparison of SSTR Antagonist [
Viswanathan R; Ballal S; Yadav MP; Roesch F; Sheokand P; Satapathy S; Tripathi M; Agarwal S; Moon ES; Bal C
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543061
[TBL] [Abstract][Full Text] [Related]
6. PET/MRI: Where might it replace PET/CT?
Ehman EC; Johnson GB; Villanueva-Meyer JE; Cha S; Leynes AP; Larson PEZ; Hope TA
J Magn Reson Imaging; 2017 Nov; 46(5):1247-1262. PubMed ID: 28370695
[TBL] [Abstract][Full Text] [Related]
7. Emerging Role of Gallium-68 DOTANOC PET/CT Guided Radiofrequency Ablation in the Treatment of Tumor-induced Osteomalacia.
Sharma J; Kasliwal R; Jain T; Sharma GK
JCEM Case Rep; 2024 May; 2(5):luae044. PubMed ID: 38660485
[TBL] [Abstract][Full Text] [Related]
8. [Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology].
Ebner R; Rübenthaler J; Ricke J; Sheikh GT; Unterrainer LM; Auernhammer CJ; Spitzweg C; Brendel M; Schmid-Tannwald C; Cyran CC
Radiologie (Heidelb); 2024 May; ():. PubMed ID: 38713221
[TBL] [Abstract][Full Text] [Related]
9. Conceptual Approach of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Chest Diseases.
Coolen J
J Belg Soc Radiol; 2016 Nov; 100(1):10. PubMed ID: 30151439
[TBL] [Abstract][Full Text] [Related]
10. EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.
Van Weehaeghe D; Lapauw B; Fraioli F; Cecchin D; Verger A; Guedj E; Albert NL; Brendel M; Yakushev I; Barthel H; Traub-Weidinger T; Tolboom N; Giessen EV
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2367-2370. PubMed ID: 38687371
[No Abstract] [Full Text] [Related]
11. Acute transient tachypnea following gadoxetate administration in a rhesus macaque during contrast-enhanced magnetic resonance imaging.
Aiosa NM; Laux J; Rojas O; Bennett RS; Logue J; Lee JH; Bollinger L; Byrum R; Claire MS; Feuerstein IM
Radiol Case Rep; 2019 Oct; 14(10):1272-1275. PubMed ID: 31462952
[TBL] [Abstract][Full Text] [Related]
12. Picture the future: emerging imaging modalities.
Lee JS; Gleeson FV
Clin Med (Lond); 2014 Dec; 14 Suppl 6():s95-9. PubMed ID: 25468929
[TBL] [Abstract][Full Text] [Related]
13. Correction to: "Emerging Role of Gallium-68 DOTANOC PET/CT Guided Radiofrequency Ablation in the Treatment of Tumor-induced Osteomalacia".
JCEM Case Rep; 2024 Jun; 2(6):luae111. PubMed ID: 38827434
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
15. International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.
Veit-Haibach P; Ahlström H; Boellaard R; Delgado Bolton RC; Hesse S; Hope T; Huellner MW; Iagaru A; Johnson GB; Kjaer A; Law I; Metser U; Quick HH; Sattler B; Umutlu L; Zaharchuk G; Herrmann K
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3513-3537. PubMed ID: 37624384
[TBL] [Abstract][Full Text] [Related]
16. PET/MRI imaging in neuroendocrine neoplasm.
Virarkar MK; Montanarella M; Itani M; Calimano-Ramirez L; Gopireddy D; Bhosale P
Abdom Radiol (NY); 2023 Dec; 48(12):3585-3600. PubMed ID: 36525051
[TBL] [Abstract][Full Text] [Related]
17. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods.
Półtorak-Szymczak G; Budlewski T; Furmanek MI; Wierzba W; Sklinda K; Walecki J; Mruk B
Front Oncol; 2021; 11():670233. PubMed ID: 34211845
[TBL] [Abstract][Full Text] [Related]
18. Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.
Pirasteh A; Lovrec P; Bodei L
Rev Endocr Metab Disord; 2021 Sep; 22(3):539-552. PubMed ID: 33783695
[TBL] [Abstract][Full Text] [Related]
19. PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?
Pirasteh A; Riedl C; Mayerhoefer ME; Giancipoli RG; Larson SM; Bodei L
Clin Transl Imaging; 2019 Dec; 7(6):405-413. PubMed ID: 33282794
[TBL] [Abstract][Full Text] [Related]
20. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer.
Velikyan I
Pharmaceuticals (Basel); 2020 Mar; 13(3):. PubMed ID: 32151049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
